1 June 2018 in Genomics, Proteomics & Bioinformatics
As a dioxygenase, Ten-Eleven Translocation 2 (TET2) catalyzes subsequent steps of 5-methylcytosine (5mC) oxidation. TET2 plays a critical role in the self-renewal, proliferation, and differentiation of hematopoietic stem cells, but its impact on mature hematopoietic cells is not well-characterized. Here we show that Tet2 plays an essential role in osteoclastogenesis. Deletion of Tet2 impairs the differentiation of osteoclast precursor cells (macrophages) and their maturation into bone-resorbing osteoclasts in vitro. Furthermore, Tet2−/− mice exhibit mild osteopetrosis, accompanied by decreased number of osteoclasts in vivo. Tet2 loss in macrophages results in the altered expression of a set of genes implicated in osteoclast differentiation, such as Cebpa, Mafb, and Nfkbiz. Tet2 deletion also leads to a genome-wide alteration in the level of 5-hydroxymethylcytosine (5hmC) and altered expression of a specific subset of macrophage genes associated with osteoclast differentiation. Furthermore, Tet2 interacts with Runx1 and negatively modulates its transcriptional activity. Our studies demonstrate a novel molecular mechanism controlling osteoclast differentiation and function by Tet2, that is, through interactions with Runx1 and the maintenance of genomic 5hmC. Targeting Tet2 and its pathway could be a potential therapeutic strategy for the prevention and treatment of abnormal bone mass caused by the deregulation of osteoclast activities.
8 May 2017 in Molecular and Clinical Oncology
The present study aimed to evaluate the effectiveness of erythropoietin (EPO) for improving cancer‑associated malignant anemia. A search was performed for randomized clinical trials, conducted according to the Cochrane manual, using electronic databases including PubMed, EMBASE, the Cochrane Library and ClinicalTrails.gov up to 15 August 2015. A total of 6 eligible studies from 5 articles enrolling a total of 453 patients were entered into the current meta-analysis. Upon EPO treatment, there were significant differences in the change in hemoglobin (HB) levels compared with the placebo at short‑term follow‑up [mean difference (MD)=0.66; 95% confidence interval (CI), 0.14‑1.18; I2=Not applicable; P=0.01) and long‑term follow‑up (MD=0.10; 95% CI, 0.02‑0.18; I2=Not applicable; P=0.01) under the random effects model. For changes in hematocrit (HCT) compared with the placebo, the results revealed there were significant differences at short‑term follow‑up (MD=2.47; 95% CI, 0.75‑4.19; I2=Not applicable; P=0.005) and long‑term follow‑up (MD=7.60; 95% CI, 6.15‑9.05; I2=Not applicable; P<0.00001) under the random effects model. Compared with the placebo in short‑term follow‑up under the fixed effects model with homogeneity, the result was a significant difference for the transfusion ratio [relative risk (RR)=0.81; 95% CI, 0.67‑ 0.97; I2=34%; P=0.02) and the transfusion requirements (MD=‑0.45; 95% CI, ‑0.92, 0.03; I2=6%; P=0.07). Funnel plots did not detect any publication bias. These results suggest that EPO was beneficial to alleviate cancer‑associated anemia and improve survival outcomes for patients with cancer.
4 April 2018 in Leukemia & Lymphoma
The clinical impact of ecotropic viral integration site 1 (EVI1) expression status in myelodysplastic syndromes (MDS) is poorly defined. Here, we investigate the expression of EVI1 and its associated clinical and cytogenetic characteristics in 398 MDS patients. High EVI1 levels (EVI1high) were found more frequently in Higher-risk MDS patients. Other cytogenetic abnormalities over-represented among EVI1high cases included complex karyotype, del(5q), monosomy 7, and 12q-compared with EVI1low MDS. No specific gene mutation was found different between EVI1high and EVI1low patients, except for a high proportion of TP53 mutation in the EVI1high group. For EVIhigh patients, mean number of gene mutations was higher than that in EVI1low patients. No definite correlation was found between EVI1 expression and MDS prognosis. However, for Higher-risk MDS patients, EVI1high patients have poorer survival rate compared with EVI1low patients. Moreover, EVI1high was an adverse prognostic marker for MDS with excess blasts subtype. The addition of EVI1 could deteriorate the survival of MDS patients with chromosome 3 abnormalities, del(5q-) or monosomy 7. Taken together, EVI1 overexpression is a poor prognostic marker for higher-risk MDS group and could be included in risk stratification for MDS patients.